HIV Prevention Product Acceptability and Preference Among Women in Sub-Saharan Africa to Inform Novel Biomedical Options in Development: A Systematic Review.
Acceptability
Biomedical options
HIV prevention
Preferences
Sub-Saharan Africa
Systematic review
Women
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
accepted:
06
10
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
aheadofprint
Résumé
The availability of several HIV prevention options may allow women to choose a product that suits their lifestyle and preferences. Product attributes and contextual factors influence product acceptability, which affects uptake and effective use. We conducted a systematic review of acceptability and preference for biomedical HIV prevention products among women in sub-Saharan Africa (SSA) to inform the development of novel products. We used a comprehensive strategy to search three databases for peer-reviewed literature from SSA published between January 2015 and December 2023. A two-stage review process assessed references against eligibility criteria. Data were abstracted using a standardized spreadsheet, then organized by constructs from two theoretical frameworks of acceptability. Results were synthesized based on product classes defined by route of administration. We identified 408 unique references; 100 references met eligibility criteria. References assessed oral PrEP (n = 65), vaginal ring (n = 44), long-acting systemic products (injectable, implant, microarray patch) (n = 28), and other vaginal products (film, insert, gel) (n = 20). Over two-thirds reported qualitative or mixed-methods data, primarily from adolescent girls and young women. Frequent dosing, especially noted for daily oral PrEP, and perceived/experienced side effects were notably negative influences. Most end-users preferred long-acting products (systemically or vaginally delivered), though on-demand products offering user control were also valued. Influencing factors, especially partners, shaped end-user perceptions of product attributes and acceptability. All products were linked to at least some barriers to uptake and/or use, highlighting the need to provide end-users with a range of options and assist them in identifying one that best suits their circumstances and needs. Biomedical HIV prevention development should advance products that address gaps in available options while optimizing favorable product attributes to achieve high acceptability that ultimately supports adoption and use.
Identifiants
pubmed: 39422786
doi: 10.1007/s10461-024-04529-2
pii: 10.1007/s10461-024-04529-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : USAID
ID : #7200AA22CA00002
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Williams KM, Miller N, Tutegyereize L, Olisa AL, Chakare T, Jeckonia P, et al. Defining principles for a choice-based approach to HIV prevention. Lancet HIV. 2023;10(4):e269–72.
pubmed: 37001965
doi: 10.1016/S2352-3018(23)00026-7
Fonner VA, Ridgeway K, van der Straten A, Lorenzetti L, Dinh N, Rodolph M, et al. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. AIDS. 2023;37(6):957–66.
pubmed: 36723489
doi: 10.1097/QAD.0000000000003494
Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (London, England). 2016;30(12):1973.
pubmed: 27149090
doi: 10.1097/QAD.0000000000001145
Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23(11):e25634.
pubmed: 33206462
pmcid: 7673220
doi: 10.1002/jia2.25634
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.
pubmed: 26900902
pmcid: 4993693
doi: 10.1056/NEJMoa1506110
UNAIDS. HIV prevention choice manifesto for women and girls in Africa launched. 2023.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.
World Health Organization. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. Geneva: World Health Organization; 2021.
World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. Genva, Switzerland: World Health Organization. 2022 Contract No.: Licence: CC BY-NC-SA 3.0 IGO.
Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Glob Health Sci Pract. 2013;1(2):203–12.
pubmed: 25276533
pmcid: 4168565
doi: 10.9745/GHSP-D-13-00010
D’Souza P, Bailey JV, Stephenson J, Oliver S. Factors influencing contraception choice and use globally: a synthesis of systematic reviews. Eur J Contracept Reprod Health Care. 2022;27(5):364–72.
pubmed: 36047713
doi: 10.1080/13625187.2022.2096215
Minnis AM, Montgomery ET, Napierala S, Browne EN, van der Straten A. Insights for implementation science from 2 multiphased studies with end-users of potential multipurpose prevention technology and HIV prevention products. JAIDS J Acquir Immune Defic Syndr. 2019;1(82):S222–9.
doi: 10.1097/QAI.0000000000002215
Ngure K, Friedland BA, Szydlo DW, Roberts ST, Garcia M, Levy L, et al. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). PLoS ONE. 2023;18(6):e0287525.
pubmed: 37352296
pmcid: 10289422
doi: 10.1371/journal.pone.0287525
Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS. 2012;7(6):534–41.
pubmed: 23032737
pmcid: 4026162
doi: 10.1097/COH.0b013e3283590632
Friedland BA, Mathur S, Haddad LB. The promise of the dual prevention pill: a framework for development and introduction. Front Reprod Health. 2021;3:682689.
pubmed: 34318291
pmcid: 8312733
doi: 10.3389/frph.2021.682689
Ortblad KF, Sekhon M, Wang L, Roth S, van der Straten A, Simoni JM, et al. Acceptability assessment in HIV prevention and treatment intervention and service delivery research: a systematic review and qualitative analysis. AIDS Behav. 2023;27(2):600–17.
pubmed: 35870025
doi: 10.1007/s10461-022-03796-1
Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: a review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;18(2):195–216.
pubmed: 23897125
doi: 10.1007/s10461-013-0560-7
Ridgeway K, Montgomery ET, Smith K, Torjesen K, van der Straten A, Achilles SL, et al. Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world. Contraception. 2022;106:16–33.
pubmed: 34644609
doi: 10.1016/j.contraception.2021.10.001
Lorenzetti L, Dinh N, van der Straten A, Fonner V, Ridgeway K, Rodolph M, et al. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition. J Int AIDS Soc. 2023;26(Suppl 2):e26107.
pubmed: 37439057
pmcid: 10805120
doi: 10.1002/jia2.26107
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.
pubmed: 19631507
doi: 10.1016/j.jclinepi.2009.06.006
Woodsong C, Holt JD. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy. Adv Drug Deliv Rev. 2015;15(92):146–54.
doi: 10.1016/j.addr.2015.02.004
Bronfenbrenner U. Ecological systems theory. In: Vasta. six theories of child development: revised formulations and current issues. Washington: American Psychological Association; 1989. p. 187–249.
Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21(5):1361–75.
pubmed: 27317411
doi: 10.1007/s10461-016-1458-y
Atujuna M, Newman PA, Wallace M, Eluhu M, Rubincam C, Brown B, et al. Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: a qualitative study. PLoS ONE. 2018;13(2):e0191251.
pubmed: 29420549
pmcid: 5805172
doi: 10.1371/journal.pone.0191251
Bazzi AR, Yotebieng KA, Agot K, Rota G, Syvertsen JL. Perspectives on biomedical HIV prevention options among women who inject drugs in Kenya. AIDS Care. 2018;30(3):343–6.
pubmed: 28780885
doi: 10.1080/09540121.2017.1363369
Beckham SW, Mantsios A, Galai N, Likindikoki S, Mbwambo J, Davis W, et al. Acceptability of multiple modalities of pre-exposure prophylaxis (PrEP) among female sex workers in Tanzania: a mixed-methods study. BMJ Open. 2022;12(8):e058611.
pubmed: 35977762
pmcid: 9389123
doi: 10.1136/bmjopen-2021-058611
Bhushan NL, Musara P, Hartmann M, Stoner MCD, Shah SR, Nabukeera J, et al. Making the case for joint decision-making in future multipurpose prevention technology (MPT) choice: qualitative findings on MPT attribute preferences from the CUPID study (MTN-045). J Int AIDS Soc. 2022;25(10):e26024.
pubmed: 36254362
pmcid: 9577116
doi: 10.1002/jia2.26024
Bjertrup PJ, Mmema N, Dlamini V, Ciglenecki I, Mpala Q, Matse S, et al. PrEP reminds me that I am the one to take responsibility of my life: a qualitative study exploring experiences of and attitudes towards pre-exposure prophylaxis use by women in Eswatini. BMC Public Health. 2021;21(1):727.
pubmed: 33853575
pmcid: 8048211
doi: 10.1186/s12889-021-10766-0
Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670.
pubmed: 34143779
pmcid: 8253429
doi: 10.1371/journal.pmed.1003670
Chimbindi N, Mthiyane N, Zuma T, Baisley K, Pillay D, McGrath N, et al. Antiretroviral therapy based HIV prevention targeting young women who sell sex: a mixed method approach to understand the implementation of PrEP in a rural area of KwaZulu-Natal, South Africa. AIDS Care. 2022;34(2):232–40.
pubmed: 33769156
doi: 10.1080/09540121.2021.1902933
Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71(4):452–61.
pubmed: 26536315
doi: 10.1097/QAI.0000000000000880
Eakle R, Bothma R, Bourne A, Gumede S, Motsosi K, Rees H. “I am still negative”: female sex workers’ perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa. PLoS ONE. 2019;14(4):e0212271.
pubmed: 30964874
pmcid: 6456175
doi: 10.1371/journal.pone.0212271
Eakle R, Bourne A, Mbogua J, Mutanha N, Rees H. Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa. J Int AIDS Soc. 2018;21(2):1.
doi: 10.1002/jia2.25081
Emmanuel G, Folayan M, Undelikwe G, Ochonye B, Jayeoba T, Yusuf A, et al. Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. BMC Public Health. 2020;20(1):69.
pubmed: 31941469
pmcid: 6964078
doi: 10.1186/s12889-020-8195-x
Fowler N, Arkell P, Abouyannis M, James C, Roberts L. Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study. AIDS Patient Care STDS. 2015;29(1):33–42.
pubmed: 25375792
doi: 10.1089/apc.2014.0210
Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Lancet Child Adolesc Health. 2020;4(12):875–83.
pubmed: 33222803
pmcid: 9832157
doi: 10.1016/S2352-4642(20)30248-0
Giovenco D, Kuo C, Underhill K, Hoare J, Operario D. Adolescent-centered HIV prevention: perspectives on acceptability of oral antiretroviral pre-exposure prophylaxis for adolescents in a global priority setting. Arch Sex Behav. 2021;50(7):2921–31.
pubmed: 34561792
pmcid: 8744480
doi: 10.1007/s10508-021-02052-2
Gombe MM, Cakouros BE, Ncube G, Zwangobani N, Mareke P, Mkwamba A, et al. Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: qualitative perspectives of general population clients at high risk for HIV. PLoS ONE. 2020;15(1):e0227632.
pubmed: 31931514
pmcid: 6957335
doi: 10.1371/journal.pone.0227632
Govender E, Abdool KQ. Understanding women and men’s acceptability of current and new HIV prevention technologies in KwaZulu-Natal, South Africa. AIDS Care. 2018;30(10):1311–4.
pubmed: 29914270
doi: 10.1080/09540121.2018.1488027
Inghels M, Kim HY, Tanser F, Hettema A, McMahon SA, Oldenburg CE, et al. PrEP uptake and delivery setting preferences among clients visiting six healthcare facilities in Eswatini. AIDS Behav. 2022;26(10):3345–55.
pubmed: 35429309
pmcid: 9474345
doi: 10.1007/s10461-022-03646-0
Kagaayi J, Batte J, Nakawooya H, Kigozi B, Nakigozi G, Strömdahl S, et al. Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda. J Int AIDS Soc. 2020;23(8):e25588.
pubmed: 32785976
pmcid: 7421540
doi: 10.1002/jia2.25588
Kawuma R, Nabalwanyi Z, Seeley J, Mayanja Y. “I prefer to take pills when I plan to have sex”: perceptions of on-demand versus daily oral pre-exposure prophylaxis among adolescents in Kampala. Uganda Afr J AIDS Res. 2022;21(1):8–14.
pubmed: 35361065
doi: 10.2989/16085906.2022.2039727
Kebaabetswe PM, Stirratt MJ, McLellan-Lemal E, Henderson FL, Gray SC, Rose CE, et al. Factors associated with adherence and concordance between measurement strategies in an HIV daily oral tenofovir/emtricitibine as pre-exposure prophylaxis (Prep) clinical trial, Botswana, 2007–2010. AIDS Behav. 2015;19(5):758–69.
pubmed: 25186785
pmcid: 4586059
doi: 10.1007/s10461-014-0891-z
Kidman R, Nachman S, Kohler HP. Interest in HIV pre-exposure prophylaxis (PrEP) among adolescents and their caregivers in Malawi. AIDS Care. 2020;32(sup2):23–31.
pubmed: 32178529
pmcid: 8073398
doi: 10.1080/09540121.2020.1742861
Kuteesa MO, Quaife M, Biraro S, Katumba KR, Seeley J, Kamali A, et al. Acceptability and predictors of uptake of anti-retroviral pre-exposure prophylaxis (PrEP) among fishing communities in Uganda: a cross-sectional discrete choice experiment survey. AIDS Behav. 2019;23(10):2674–86.
pubmed: 30734882
doi: 10.1007/s10461-019-02418-7
Lahuerta M, Zerbe A, Baggaley R, Falcao J, Ahoua L, DiMattei P, et al. Feasibility, acceptability, and adherence with short-term HIV preexposure prophylaxis in female sexual partners of migrant miners in Mozambique. J Acquir Immune Defic Syndr. 2017;76(4):343–7.
pubmed: 28777264
pmcid: 5662163
doi: 10.1097/QAI.0000000000001518
Lancaster KE, Lungu T, Bula A, Shea JM, Shoben A, Hosseinipour MC, et al. Preferences for pre-exposure prophylaxis service delivery among female sex workers in Malawi: a discrete choice experiment. AIDS Behav. 2020;24(5):1294–303.
pubmed: 31720955
pmcid: 7995177
doi: 10.1007/s10461-019-02705-3
Little KM, Flomen L, Hanif H, Anderson SM, Thurman AR, Clark MR, et al. HIV pre-exposure prophylaxis implant stated preferences and priorities: results of a discrete choice experiment among women and adolescent girls in Gauteng Province, South Africa. AIDS Behav. 2022;26(9):3099–109.
pubmed: 35360893
pmcid: 9371991
doi: 10.1007/s10461-022-03658-w
Luecke EH, Cheng H, Woeber K, Nakyanzi T, Mudekunye-Mahaka IC, van der Straten A. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study. J Int AIDS Soc. 2016;19(1):20875.
pubmed: 27247202
pmcid: 4887458
doi: 10.7448/IAS.19.1.20875
Mbewe L, Govender E. Male partners’ influence on women’s acceptance and use of PrEP products across two high HIV-burdened districts in South Africa. Afr J AIDS Res. 2020;19(2):93–100.
pubmed: 32320329
doi: 10.2989/16085906.2020.1727932
Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, et al. Young women’s stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80(4):394–403.
pubmed: 30633040
pmcid: 6410963
doi: 10.1097/QAI.0000000000001945
Minnis AM, Etima J, Musara P, Browne EN, Mutero P, Kemigisha D, et al. Couples’ Preferences for “2 in 1” multipurpose prevention technologies to prevent both HIV and pregnancy: results of a discrete choice experiment in Uganda and Zimbabwe. AIDS Behav. 2022;8:1–14. https://doi.org/10.1007/s10461-022-03713-6 .
doi: 10.1007/s10461-022-03713-6
Minnis AM, Krogstad E, Shapley-Quinn MK, Agot K, Ahmed K, Danielle Wagner L, et al. Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa. Sex Reprod Health Matters. 2021;29(1):1927477.
pubmed: 34224341
pmcid: 8259853
Minnis AM, Roberts ST, Agot K, Weinrib R, Ahmed K, Manenzhe K, et al. Young women’s ratings of three placebo multipurpose prevention technologies for HIV and pregnancy prevention in a randomized, cross-over study in Kenya and South Africa. AIDS Behav. 2018;22(8):2662–73.
pubmed: 29560570
pmcid: 6097726
doi: 10.1007/s10461-018-2078-5
Montgomery ET, Atujuna M, Krogstad E, Hartmann M, Ndwayana S, O’Rourke S, et al. The invisible product: preferences for sustained-release, long-acting pre-exposure prophylaxis to HIV among South African youth. J Acquir Immune Defic Syndr. 2019;80(5):542–50.
pubmed: 30865050
pmcid: 6426447
doi: 10.1097/QAI.0000000000001960
Montgomery ET, van der Straten A, Stadler J, Hartmann M, Magazi B, Mathebula F, et al. Male partner influence on women’s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of “Understanding.” AIDS Behav. 2015;19(5):784–93.
pubmed: 25416076
pmcid: 4416996
doi: 10.1007/s10461-014-0950-5
Mudzviti T, Dhliwayo A, Chingombe B, Ngara B, Monera-Penduka TG, Maponga CC, et al. Perspectives on oral pre-exposure prophylaxis use amongst female sex workers in Harare, Zimbabwe. South Afr J HIV Med. 2020. https://doi.org/10.4102/sajhivmed.v21i1.1039 .
doi: 10.4102/sajhivmed.v21i1.1039
pubmed: 33354366
pmcid: 7736656
Muhumuza R, Ssemata AS, Kakande A, Ahmed N, Atujuna M, Nomvuyo M, et al. Exploring perceived barriers and facilitators of PrEP uptake among young people in Uganda, Zimbabwe, and South Africa. Arch Sex Behav. 2021;50(4):1729–42.
pubmed: 33954824
pmcid: 8213546
doi: 10.1007/s10508-020-01880-y
Nakamanya S, Kawuma R, Kibuuka D, Kusemererwa S, McCormack S, Ruzagira E, et al. Assessing acceptability of pre-exposure prophylaxis (PrEP) among participants in an HIV vaccine preparedness study in southwestern Uganda. PLoS ONE. 2022;17(7):e0271104.
pubmed: 35905052
pmcid: 9337655
doi: 10.1371/journal.pone.0271104
Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J, Guest G, et al. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health Sex. 2016;18(9):1081–91.
pubmed: 27093238
pmcid: 5049692
doi: 10.1080/13691058.2016.1164899
Nyblade L, Ndirangu JW, Speizer IS, Browne FA, Bonner CP, Minnis A, et al. Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women: conflicting perspectives in South Africa. BMC Public Health. 2022;22(1):1916.
pubmed: 36242000
pmcid: 9563466
doi: 10.1186/s12889-022-14236-z
Ongolly FK, Dolla A, Ngure K, Irungu EM, Odoyo J, Wamoni E, et al. “I Just Decided to Stop:” understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya. J Acquir Immune Defic Syndr. 2021;87(1):E150–8.
pubmed: 33492024
pmcid: 8026512
doi: 10.1097/QAI.0000000000002625
Pintye J, Beima-Sofie KM, Kimemia G, Ngure K, Trinidad SB, Heffron RA, et al. “I Did Not Want to Give Birth to a Child Who has HIV”: experiences using PrEP during pregnancy among HIV-uninfected Kenyan women in HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2017;76(3):259–65.
pubmed: 28777265
pmcid: 5634917
doi: 10.1097/QAI.0000000000001516
Pintye J, Beima-Sofie KM, Makabong’O PA, Njoroge A, Trinidad SB, Heffron RA, et al. HIV-uninfected Kenyan adolescent and young women share perspectives on using preexposure prophylaxis during pregnancy. Aids Patient Care STDS. 2018;32(12):538–44.
pubmed: 30036072
pmcid: 6300042
doi: 10.1089/apc.2018.0058
Pintye J, O’Malley G, Kinuthia J, Abuna F, Escudero JN, Mugambi M, et al. Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. J Acquir Immune Defic Syndr. 2021;86(4):e83–9.
pubmed: 33273211
pmcid: 8935942
doi: 10.1097/QAI.0000000000002587
Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M, et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Mak. 2018;38(1):120–33.
doi: 10.1177/0272989X17729376
Restar AJ, Tocco JU, Mantell JE, Lafort Y, Gichangi P, Masvawure TB, et al. Perspectives on HIV pre- and post-exposure prophylaxes (PrEP and PEP) among female and male sex workers in Mombasa, Kenya: implications for integrating biomedical prevention into sexual health services. AIDS Educ Prev. 2017;29(2):141–53.
pubmed: 28467163
pmcid: 5706461
doi: 10.1521/aeap.2017.29.2.141
Roberts ST, Haberer J, Celum C, Mugo N, Ware NC, Cohen CR, et al. Intimate partner violence and adherence to HIV pre-exposure prophylaxis (PrEP) in African women in HIV serodiscordant relationships: a prospective cohort study. J Acquir Immune Defic Syndr. 2016;73(3):313–22.
pubmed: 27243900
pmcid: 5065369
doi: 10.1097/QAI.0000000000001093
Sarr M, Gueye D, Mboup A, Diouf O, Bao MDB, Ndiaye AJ, et al. Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal. Int J STD AIDS. 2020;31(11):1063–72.
pubmed: 32819210
pmcid: 7750667
doi: 10.1177/0956462420943704
Sekhon M, van der Straten A. Pregnant and breastfeeding women’s prospective acceptability of two biomedical HIV prevention approaches in Sub Saharan Africa: a multisite qualitative analysis using the theoretical framework of acceptability. PLoS ONE. 2021;16(11):e0259779.
pubmed: 34784355
pmcid: 8594804
doi: 10.1371/journal.pone.0259779
Shamu S, Shamu P, Khupakonke S, Farirai T, Chidarikire T, Guloba G, et al. Pre-exposure prophylaxis (PrEP) awareness, attitudes and uptake willingness among young people: gender differences and associated factors in two South African districts. Glob Health Action. 2021;14(1):1886455.
pubmed: 33606603
pmcid: 7899653
doi: 10.1080/16549716.2021.1886455
Shapley-Quinn MK, Manenzhe KN, Agot K, Minnis AM, van der Straten A. “We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study. Int J Womens Health. 2019;11:97–107.
pubmed: 30799959
pmcid: 6369839
doi: 10.2147/IJWH.S185712
Sila J, Larsen AM, Kinuthia J, Owiti G, Abuna F, Kohler PK, et al. High awareness, yet low uptake, of pre-exposure prophylaxis among adolescent girls and young women within family planning clinics in Kenya. AIDS Patient Care STDS. 2020;34(8):336–43.
pubmed: 32757980
pmcid: 7415219
doi: 10.1089/apc.2020.0037
Sullivan K, Mtande T, Jaffe E, Rosenberg N, Zimba C, Hoffman I, et al. Views among Malawian women about joining HIV prevention clinical trials when pregnant. AIDS Res Ther. 2020. https://doi.org/10.1186/s12981-020-00271-6 .
doi: 10.1186/s12981-020-00271-6
pubmed: 32460804
pmcid: 7251879
Tubert J, Packel L, Hunter LA, Mfaume R, Njau P, Ramadhani AA, et al. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania. AIDS Res Ther. 2021;18(1):21.
pubmed: 33902623
pmcid: 8074434
doi: 10.1186/s12981-021-00343-1
van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K, et al. The tablets, ring, injections as options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21(3):e25094.
pubmed: 29600595
pmcid: 5876496
doi: 10.1002/jia2.25094
van der Straten A, Ryan JH, Reddy K, Etima J, Taulo F, Mutero P, et al. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. J Int AIDS Soc. 2020;23(6):e25536.
pubmed: 32524700
pmcid: 7287313
doi: 10.1002/jia2.25536
Wagner LD, Minnis AM, Shea J, Agot K, Ahmed K, van der Straten A. Female and male partner perspectives on placebo multipurpose prevention technologies (MPTs) used by women in the TRIO study in South Africa and Kenya. PLoS ONE. 2022;17(5):e0265303.
pubmed: 35551318
pmcid: 9097999
doi: 10.1371/journal.pone.0265303
Weinrib R, Minnis A, Agot K, Ahmed K, Owino F, Manenzhe K, et al. End-users’ product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. AIDS Behav. 2018;22(1):133–45.
pubmed: 29052018
doi: 10.1007/s10461-017-1911-6
Witte SS, Filippone P, Ssewamala FM, Nabunya P, Bahar OS, Mayo-Wilson LJ, et al. PrEP acceptability and initiation among women engaged in sex work in Uganda: implications for HIV prevention. EClinicalMedicine. 2022;44:101278.
pubmed: 35128367
pmcid: 8808048
doi: 10.1016/j.eclinm.2022.101278
Lunkuse JF, Kamacooko O, Muturi-Kioi V, Chinyenze K, Kuteesa MO, Price MA, et al. Low awareness of oral and injectable PrEP among high-risk adolescent girls and young women in Kampala, Uganda. BMC Infect Dis. 2022;22(1):467.
pubmed: 35578163
pmcid: 9109298
doi: 10.1186/s12879-022-07398-z
Mayanja Y, Kamacooko O, Lunkuse JF, Muturi-Kioi V, Buzibye A, Omali D, et al. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study. J Int AIDS Soc. 2022;25(5):e25909.
pubmed: 35543110
pmcid: 9092160
doi: 10.1002/jia2.25909
Musara P, Hartmann M, Ryan JH, Reddy K, Ggita J, Mutero P, et al. Understanding the role of men in women’s use of the vaginal ring and oral PrEP during pregnancy and breastfeeding: multi-stakeholder perspectives. Afr J AIDS Res. 2022;21(4):354–63.
pubmed: 36538544
pmcid: 9983781
doi: 10.2989/16085906.2022.2138474
Montgomery ET, Hawley I, Fairlie L, Bunge K, Mathebula F, Etima J, et al. Acceptability of the dapivirine vaginal ring and oral truvada among african users in late-stage of pregnancy. AIDS Behav. 2023;2(8):963.
van der Straten A, Shapley-Quinn MK, Reddy K, Cheng H, Etima J, Woeber K, et al. Favoring “peace of Mind”: a qualitative study of African women’s HIV prevention product formulation preferences from the MTN-020/ASPIRE trial. AIDS Patient Care STDS. 2017;31(7):305–14.
pmcid: 5512310
doi: 10.1089/apc.2017.0075
Montgomery ET, Beksinska M, Mgodi N, Schwartz J, Weinrib R, Browne EN, et al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J Int AIDS Soc. 2019;22(5):e25283.
pubmed: 31069957
pmcid: 6506690
doi: 10.1002/jia2.25283
Govender EM, Mansoor LE, Abdool KQ. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. AIDS Care. 2017;29(6):734–40.
pubmed: 27799005
doi: 10.1080/09540121.2016.1248349
MacQueen KM, Dlamini S, Perry B, Okumu E, Sortijas S, Singh C, et al. Social context of adherence in an open-label 1 % tenofovir gel trial: gender dynamics and disclosure in KwaZulu-Natal. South Africa AIDS and behavior. 2016;20(11):2682–91.
pubmed: 26945585
doi: 10.1007/s10461-016-1339-4
Miller L, Morar N, Kapiga S, Ramjee G, Hayes R. Prevention, partners, and power imbalances: women’s views on how male partners affected their adherence to vaginal microbicide gels during HIV prevention trials in Africa. J Acquir Immune Defic Syndr. 2020;85(4):458–65.
pubmed: 33136745
pmcid: 7993915
doi: 10.1097/QAI.0000000000002463
Miller L, Morar N, Kapiga S, Ramjee G, Hayes R. Women design their own vaginal microbicide trial: suggestions on how to improve adherence from former participants of HIV prevention trials. PLoS ONE. 2021;16(1):e0244652.
pubmed: 33411782
pmcid: 7790400
doi: 10.1371/journal.pone.0244652
Musara P, Milford C, Shapley-Quinn MK, Weinrib R, Mutero P, Odoom E, et al. Preferences and acceptability of vaginal delivery forms for HIV prevention among women, male partners and key informants in South Africa and Zimbabwe: qualitative findings. AIDS Behav. 2021;25(1):124–38.
pubmed: 32588257
doi: 10.1007/s10461-020-02949-4
Schuler SR, Bukusi E. Male engagement in women’s microbicide use in Kenya: navigating gender norms. Health Care Women Int. 2017;38(5):507–19.
pubmed: 28273003
doi: 10.1080/07399332.2017.1292277
Weinrib R, Browne EN, Shapley-Quinn MK, van der Straten A, Beksinska M, Mgodi N, et al. Perspectives from young South African and Zimbabwean women on attributes of four (placebo) vaginal microbicide delivery forms. AIDS Behav. 2020;24(2):637–47.
pubmed: 31254190
doi: 10.1007/s10461-019-02576-8
Browne EN, Montgomery ET, Mansfield C, Boeri M, Mange B, Beksinska M, et al. Efficacy is not everything: eliciting women’s preferences for a vaginal HIV prevention product using a discrete-choice experiment. AIDS Behav. 2020;24(5):1443–51.
pubmed: 31696371
doi: 10.1007/s10461-019-02715-1
Hart CW, Joanis C, Hartmann M, Milford C, Smit J, Beksinska M, et al. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa. Eur J Contracept Reprod Health Care. 2019;24(5):390–8.
pubmed: 31517545
doi: 10.1080/13625187.2019.1656188
Laborde ND, Leslie J, Krogstad E, Morar N, Mutero P, Etima J, et al. Perceptions of the “Fabric”—an exploratory study of a novel multi-purpose technology among women in Sub Saharan Africa. PLoS ONE. 2018;13(10):e0204821.
pubmed: 30379839
pmcid: 6209182
doi: 10.1371/journal.pone.0204821
Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T, et al. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Cult Health Sex. 2019;21(11):1209–24.
pubmed: 30657023
pmcid: 6639142
doi: 10.1080/13691058.2018.1552989
Duby Z, Katz AWK, Browne EN, Mutero P, Etima J, Zimba CC, et al. Hygiene, blood flow, and vaginal overload: why women removed an HIV Prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2020;24(2):617–28.
pubmed: 31030301
pmcid: 6815681
doi: 10.1007/s10461-019-02514-8
Kabarambi A, Kusemererwa S, Krogstad E, Mayaud P, Seeley J, Mugisha J, et al. The dapivirine vaginal ring from the perspective of married men in Uganda. Afr J AIDS Res. 2021;20(1):53–60.
pubmed: 33632073
doi: 10.2989/16085906.2020.1866043
Katz AWK, Mansoor LE, Tsidya M, Mathebula F, Singh D, Siva S, et al. Using emoji stickers to understand end-user opinions of the dapivirine vaginal ring for HIV prevention. AIDS Behav. 2021;25(12):3955–66.
pubmed: 34180041
pmcid: 8631950
doi: 10.1007/s10461-021-03338-1
Katz AWK, Naidoo K, Reddy K, Chitukuta M, Nabukeera J, Siva S, et al. The power of the shared experience: MTN-020/ASPIRE trial participants’ descriptions of peer influence on acceptability of and adherence to the dapivirine vaginal ring for HIV prevention. AIDS Behav. 2020;24(8):2387–99.
pubmed: 31980993
pmcid: 8631948
doi: 10.1007/s10461-020-02799-0
Mayo AJ, Browne EN, Montgomery ET, Torjesen K, Palanee-Phillips T, Jeenarain N, et al. Acceptability of the dapivirine vaginal ring for HIV-1 prevention and association with adherence in a phase III trial. AIDS Behav. 2021;25(8):2430–40.
pubmed: 33713213
pmcid: 8222015
doi: 10.1007/s10461-021-03205-z
McLellan-Lemal E, Deaton SR, Betts JE, Ondenge K, Mudhune V, O’Connor SM, et al. Acceptability of an intravaginal ring for simultaneously preventing HIV infection and pregnancy: qualitative findings of the Kisumu combined ring study, 2019. Contemp Clin Trials. 2022;122:106935.
pubmed: 36162740
pmcid: 11265295
doi: 10.1016/j.cct.2022.106935
Montgomery ET, Stadler J, Naidoo S, Katz AWK, Laborde N, Garcia M, et al. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results. AIDS. 2018;32(11):1517–25.
pubmed: 29957723
doi: 10.1097/QAD.0000000000001868
Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–67.
pubmed: 28441175
doi: 10.1097/QAD.0000000000001452
Naidoo K, Mansoor LE, Katz AWK, Garcia M, Kemigisha D, Morar NS, et al. Qualitative perceptions of dapivirine VR adherence and drug level feedback following an open-label extension trial. J Acquir Immune Defic Syndr. 2021;86(4):e90–6.
pubmed: 33278181
pmcid: 7902420
doi: 10.1097/QAI.0000000000002590
Reddy K, Mathebula F, Katz A, Luecke E, Tenza S, Palanee-Phillips T, et al. Ring-ing in the future: participant and male partner perspectives regarding future use of the dapivirine vaginal ring for HIV prevention. AIDS Behav. 2022;26(6):1923–32.
pubmed: 35064389
pmcid: 9050873
doi: 10.1007/s10461-021-03542-z
van der Straten A, Browne EN, Shapley-Quinn MK, Brown ER, Reddy K, Scheckter R, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81(3):304–10.
pubmed: 30844995
pmcid: 6571014
doi: 10.1097/QAI.0000000000002028
Zhao X, Milford C, Smit J, Zulu B, Boyd P, Malcolm RK, et al. Color, scent and size: exploring women’s preferences around design characteristics of drug-releasing vaginal rings. AIDS Behav. 2022;26(9):2954–68.
pubmed: 35294694
pmcid: 8924943
doi: 10.1007/s10461-022-03596-7
Morar NS, Mansoor LE, Naidoo K, Katz AWK, Garcia M, Duma C, et al. Male partner opinions of the dapivirine vaginal ring used during an open-label extension HIV prevention trial in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2023;92(2):127–33.
pubmed: 36302179
pmcid: 9839591
doi: 10.1097/QAI.0000000000003119
Browne EN, Torjesen K, Mirembe BG, Palanee-Phillips T, Jeenarain N, Chitukuta M, et al. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex. AIDS Care. 2024;36(1):80–6.
pubmed: 37066990
doi: 10.1080/09540121.2023.2198187
Krogstad EA, Atujuna M, Montgomery ET, Minnis A, Ndwayana S, Malapane T, et al. Perspectives of South African youth in the development of an implant for HIV prevention. J Int AIDS Soc. 2018;21(8):e25170.
pubmed: 30152004
pmcid: 6111144
doi: 10.1002/jia2.25170
Minnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo S, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc. 2020;23(6):e25528.
pubmed: 32544303
pmcid: 7297460
doi: 10.1002/jia2.25528
Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). J Int AIDS Soc. 2019;22(10):e25408.
pubmed: 31651098
pmcid: 6813716
doi: 10.1002/jia2.25408
Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, et al. Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077. AIDS Behav. 2020;24(9):2520–31.
pubmed: 32052214
pmcid: 7423859
doi: 10.1007/s10461-020-02808-2
Ismail A, Magni S, Katahoire A, Ayebare F, Siu G, Semitala F, et al. Exploring user and stakeholder perspectives from South Africa and Uganda to refine microarray patch development for HIV PrEP delivery and as a multipurpose prevention technology. PLoS ONE. 2023;18(8):e0290568.
pubmed: 37651432
pmcid: 10470907
doi: 10.1371/journal.pone.0290568
Gachigua SG, Karuga R, Ngunjiri A, Jarrahian C, Coffey PS, Kilbourne-Brook M, et al. Microarray patch for HIV prevention and as a multipurpose prevention technology to prevent HIV and unplanned pregnancy: an assessment of potential acceptability, usability, and programmatic fit in Kenya. Front Reprod Health. 2023;5:1125159.
pubmed: 37168102
pmcid: 10164997
doi: 10.3389/frph.2023.1125159
Nkomo S, Makoni W, Shapley-Quinn MK, Luecke E, Mbatsane E, Manenzhe K, et al. Prospective acceptability of a multipurpose technology (MPT) implant in preclinical development to prevent HIV and unplanned pregnancy: qualitative insights from women end users and health care providers in South Africa and Zimbabwe. PLoS ONE. 2023;18(5):e0285711.
pubmed: 37195918
pmcid: 10191314
doi: 10.1371/journal.pone.0285711
Mataboge P, Mthimkhulu N, Kutywayo A, Martin CE, Mazibuko M, Kwatsha K, et al. Preferences, educational messaging, and demand creation channels for multipurpose-prevention technologies (MPTs) among women in South Africa. BMC Public Health. 2023;23(1):2090.
pubmed: 37880628
pmcid: 10598950
doi: 10.1186/s12889-023-16904-0
Stoner MCD, Rucinski KB, Giovenco D, Gill K, Morton JF, Bekker LG, et al. Trajectories of PrEP adherence among young women aged 16 to 25 in Cape Town, South Africa. AIDS Behav. 2021;25(7):2046–53.
pubmed: 33389323
pmcid: 8169554
doi: 10.1007/s10461-020-03134-3
Mansoor LE, Lewis L, Naicker CL, Harkoo I, Dawood H, Naidoo K, et al. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa. J Int AIDS Soc. 2022;25(7):e25957.
pubmed: 35785472
pmcid: 9251857
doi: 10.1002/jia2.25957
Haberer JE, Mugo N, Bukusi EA, Ngure K, Kiptinness C, Oware K, et al. Understanding pre-exposure prophylaxis adherence in young women in Kenya. J Acquir Immune Defic Syndr. 2022;89(3):251–60.
pubmed: 35147580
doi: 10.1097/QAI.0000000000002876
Scorgie F, Khoza N, Delany-Moretlwe S, Velloza J, Mangxilana N, Atujuna M, et al. Narrative sexual histories and perceptions of HIV risk among young women taking PrEP in southern Africa: findings from a novel participatory method. Soc Sci Med. 2021;270:113600.
pubmed: 33360535
doi: 10.1016/j.socscimed.2020.113600
Ngure K, Thuo N, Ogello V, Kiptinness C, Kamolloh K, Burns BFO, et al. Dynamic perceived HIV risk and sexual behaviors among young women enrolled in a PrEP trial in Kenya: a qualitative study. Front Reprod Health. 2021;3:637869.
pubmed: 36304002
pmcid: 9580724
doi: 10.3389/frph.2021.637869
Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, et al. HIV preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among Cisgender women. JAMA. 2024;331(11):930–7.
pubmed: 38427359
pmcid: 10951736
doi: 10.1001/jama.2024.0464
Ngure K. Choice and adherence to dapivirine ring or oral PrEP by young African women in REACH. Conference for retroviruses and opportunistic infections (CROI); Virtual 20222022. 2022
Torjesen K, Irungu E. The CATALYST Study Protocol Version 2.0. 2023; https://www.prepwatch.org/wp-content/uploads/2023/10/CATALYST-Study-Protocol.pdf .